WITTEN, Germany--(BUSINESS WIRE)--According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of less than USD130,000 in the course of its financial year 2015, ended June 30, 2015. In the financial year 2014 revenues amounted to USD133,470. Revenues in the fourth quarter came in at around USD11,000 (Q4/2014: USD43,729). Royalties from the licensing agreement regarding the wound treatment product Granulox engrossed by SanguiBio
| < Prev | Next > |
|---|
